Sangretech Biomedical will provide Bostwick Scientific with exclusive rights to its dendritic-cell technology in certain territories. Sangretech’s technology will be used in the development and commercialization of VDC2008, Bostwick Scientific’s clinical-stage product candidate employing unloaded or virgin dendritic cells in combination with cryotherapy and other primary therapies to potentially treat prostate and other solid cancers.  

Previous articleRoche Gains Access to Cerep’s Pharmacology and ADME Database
Next articleClemson University Obtains $9.3M for Tissue Regeneration Center